Open Access and Peer-reviewed
Home Journal Issues Guide for Authors Editorial Board Aims & Scope About Journal News & Announcements


Original Research 
RMJ. 2019; 44(2): 302-307


Efficacy of paliperidone palmitate on psychiatric symptoms and attitudes toward medication in schizophrenia

Bong Ju Lee.

Abstract
Objective: To examine the efficacy of once-monthly paliperidone palmitate (PP1M) on symptoms and attitudes toward medication in individuals with schizophrenia.
Methodology: Out of 52 subjects with schizophrenia, 43 were included in the study. The Positive and Negative Syndrome Scale (PANSS) and the ten-item Drug Attitude Inventory (DAI) were used to collect data. With a cut-off score of 4 on the DAI, subjects were divided into two groups: adherent and non-adherent. A paired t-test was also performed for comparison between two different assessment time points.
Results: During a 1-year study period with PP1M, both groups showed improvement in their symptoms. The change in DAI was significant and both groups showed improvement in DAI score. Subjects with a low DAI score at baseline showed shorter treatment duration compared with subjects with a higher score at baseline.
Conclusions: PP1M was effective in improving symptoms and positively changing attitudes toward medication in individuals with schizophrenia. Therefore, it may have promising effects cation in individuals with schizophrenia.

Key words: Schizophrenia, drug Attitude Inventory, paliperidone palmitate


 
ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Bong Ju Lee
on Google
on Google Scholar
Article Statistics
 Viewed: 800
Downloaded: 1
Cited: 0


How to Cite this Article
Pubmed Style

Bong Ju Lee. Efficacy of paliperidone palmitate on psychiatric symptoms and attitudes toward medication in schizophrenia. RMJ. 2019; 44(2): 302-307.


Web Style

Bong Ju Lee. Efficacy of paliperidone palmitate on psychiatric symptoms and attitudes toward medication in schizophrenia. http://www.rmj.org.pk/?mno=26572 [Access: August 25, 2019].


AMA (American Medical Association) Style

Bong Ju Lee. Efficacy of paliperidone palmitate on psychiatric symptoms and attitudes toward medication in schizophrenia. RMJ. 2019; 44(2): 302-307.



Vancouver/ICMJE Style

Bong Ju Lee. Efficacy of paliperidone palmitate on psychiatric symptoms and attitudes toward medication in schizophrenia. RMJ. (2019), [cited August 25, 2019]; 44(2): 302-307.



Harvard Style

Bong Ju Lee (2019) Efficacy of paliperidone palmitate on psychiatric symptoms and attitudes toward medication in schizophrenia. RMJ, 44 (2), 302-307.



Turabian Style

Bong Ju Lee. 2019. Efficacy of paliperidone palmitate on psychiatric symptoms and attitudes toward medication in schizophrenia. Rawal Medical Journal, 44 (2), 302-307.



Chicago Style

Bong Ju Lee. "Efficacy of paliperidone palmitate on psychiatric symptoms and attitudes toward medication in schizophrenia." Rawal Medical Journal 44 (2019), 302-307.



MLA (The Modern Language Association) Style

Bong Ju Lee. "Efficacy of paliperidone palmitate on psychiatric symptoms and attitudes toward medication in schizophrenia." Rawal Medical Journal 44.2 (2019), 302-307. Print.



APA (American Psychological Association) Style

Bong Ju Lee (2019) Efficacy of paliperidone palmitate on psychiatric symptoms and attitudes toward medication in schizophrenia. Rawal Medical Journal, 44 (2), 302-307.








AUTHOR LOGIN

REVIEWER LOGIN

Indexed
&
Abstracted


Indexed in WHO Index Medicus IMEMR, Emromedex, Pakmedinet, ExtraMED and Scopus

  Approved by the Higher Education Commission of Pakistan and Pakistan Medical and Dental Council


ABOUT JOURNAL
POLICIES
STATEMENTS

This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access.

The articles in Rawal Medical Journal are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.